 |
[Apha Biz=(Chicago) Reporter Paul Lee] SD Biosensor, an in vitro diagnostic company, made an announcement on the 11th that it turned into a deficit of 76.4 billion won in operating losses based on consolidation in the second quarter.
Sales fell 83% year-on-year to 162.6 billion won. Net profit also shifted to deficit.
As a result, SD Biosensor's consolidated sales in the first half of the year were 345 billion won and operating losses were 174.2 billion won.
The company explained that the costs of setting up inventory asset reserves for Indian, Brazilian and Indonesian subsidiaries in the second quarter and accounting costs without cash outflows were incurred due to consolidated accounting by Meridian Bioscience, a U.S. diagnostic company it acquired earlier this year.
In addition, research and development (R&D) and product registration for new product development cost about 4 billion won per month. Meridian's second-quarter sales reached 75.1 billion won.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
